Regeneron Pharmaceuticals, Inc. REGN
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 1.95B | 1.30B | 727.20M | 844.60M | 1.46B |
| Total Depreciation and Amortization | 121.00M | 123.70M | 123.20M | 145.00M | 136.70M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 104.30M | 41.60M | 192.00M | 175.20M | -603.00M |
| Change in Net Operating Assets | -390.60M | -649.20M | 36.50M | 5.90M | 625.00M |
| Cash from Operations | 1.78B | 813.00M | 1.08B | 1.17B | 1.62B |
| Capital Expenditure | -300.20M | -240.20M | -230.60M | -248.70M | -201.40M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -300.00K | -3.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 12.10M | 147.50M | -198.30M | 469.30M | -198.50M |
| Cash from Investing | -288.10M | -92.70M | -428.90M | 220.30M | -402.90M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 300.90M | 49.20M | 163.10M | 503.50M | 40.30M |
| Repurchase of Common Stock | -495.40M | -1.18B | -867.50M | -1.19B | -667.00M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -95.70M | -96.80M | -97.80M | -92.70M | -91.20M |
| Other Financing Activities | -- | -- | -- | 0.00 | 0.00 |
| Cash from Financing | -290.20M | -1.22B | -802.20M | -780.10M | -717.90M |
| Foreign Exchange rate Adjustments | 500.00K | -300.00K | -900.00K | -300.00K | -400.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.21B | -504.60M | -153.10M | 610.60M | 497.50M |